Lung Life AI CEO Shares Regulatory And Reimbursement Journey For Lung Cancer Diagnostic, Lung LB

episode

Citeline Podcasts not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

Related

recent transcribed audio

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury (Hour 2) 40 min · 24 Sep 2026 · Rahimi & Grote Show

Cubs squander chance to clinch playoff berth in losing to Marlins, 3-2 (Hour 1) 42 min · 24 Sep 2026 · Rahimi & Grote Show

Danny Parkins sounds off on discourse surrounding Caleb Williams' injury 19 min · 24 Sep 2026 · Rahimi & Grote Show

710: That New Mouse Pad Feeling 2h 13m · 24 Sep 2026 · Accidental Tech Podcast

Steven Bartlett REVEALS the Secret Behind the World’s Fastest Growing Podcast | PBD Podcast #861 1h 27m · 24 Sep 2026 · PBD Podcast

1PM ET 09/24/2026 Newscast 3 min · 24 Sep 2026 · Fox News Hourly Update

Report any issue

Source

Recorded21 Jun 2024

Publisherfeeds.soundcloud.com ↗

Handlerec:4677769

Show notes

In this episode, Medtech Insight reporter Natasha Barrow speaks to LungLife AI CEO Paul Pagano. Lung Life AI is a US-based AIM-listed medical technology company that has developed a liquid biopsy test for the early detection of lung cancer called Lung LB. Pagano runs through the highlights of Lung Life AI’s journey to date and its future ambition for a strategic partnership. He also provides advice to similar diagnostic companies seeking reimbursement and compliance with the US FDA Lab Developed Test ruling.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in